Source:http://linkedlifedata.com/resource/pubmed/id/15729481
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2005-2-24
|
pubmed:abstractText |
We studied the antimicrobial susceptibility of AmpC beta-lactamase-producing Escherichia coli isolates collected at ten medical institutions in the Kinki area of Japan during a 6-month period (November 2002 through April 2003). Of 2845 E. coli isolates tested, 29 (1.0%) showed a minimum inhibitory concentration (MIC) for cefazolin of more than 8 microg/ml and were three-dimensional extract test positive. In standard inoculum susceptibility tests against these 29 strains, the MIC90s for the four carbapenems tested ranged from 0.06 microg/ml to 0.5 microg/ml, and these compounds were more active than the other beta-lactams, with meropenem being the most active. The MIC90s for beta-lactams, except carbapenems, ranged from 4 microg/ml to 32 microg/ml, with cefepime being the most active. In high inoculum susceptibility tests against these strains, the MIC90s for the four carbapenems and cefepime were 8 microg/ml or less, and these compounds were more active than other beta-lactams. The MIC90s for beta-lactams, except carbapenems and cefepime, were 32 microg/ml or more. The MIC90s for the five quinolones tested ranged from 4 microg/ml to 16 microg/ml, and the order of increasing susceptibility was ciprofloxacin > levofloxacin, gatifloxacin and pazufloxacin > prulifloxacin.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/AmpC beta-lactamases,
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Bacterial Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Bacterial Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Cefazolin,
http://linkedlifedata.com/resource/pubmed/chemical/Quinolones,
http://linkedlifedata.com/resource/pubmed/chemical/beta-Lactamases
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
1341-321X
|
pubmed:author |
pubmed-author:AiharaMasanoriM,
pubmed-author:HiguchiTakeshiT,
pubmed-author:KinoshitaShohiroS,
pubmed-author:KofukuTomomiT,
pubmed-author:KomatsuMasaruM,
pubmed-author:NishioHisaakiH,
pubmed-author:OritaTamakiT,
pubmed-author:SakamotoMasakoM,
pubmed-author:SatohKaoriK,
pubmed-author:ShimakawaKoichiK,
pubmed-author:SueyoshiNoriyukiN,
pubmed-author:ToyokawaMasahiroM,
pubmed-author:WadaYasunaoY,
pubmed-author:YamasakiKatsutoshiK,
pubmed-author:YamashitaTomonariT
|
pubmed:issnType |
Print
|
pubmed:volume |
11
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
9-13
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:15729481-Anti-Bacterial Agents,
pubmed-meshheading:15729481-Bacterial Proteins,
pubmed-meshheading:15729481-Cefazolin,
pubmed-meshheading:15729481-Cross Infection,
pubmed-meshheading:15729481-Escherichia coli,
pubmed-meshheading:15729481-Escherichia coli Infections,
pubmed-meshheading:15729481-Hospitals,
pubmed-meshheading:15729481-Humans,
pubmed-meshheading:15729481-Japan,
pubmed-meshheading:15729481-Microbial Sensitivity Tests,
pubmed-meshheading:15729481-Quinolones,
pubmed-meshheading:15729481-beta-Lactamases
|
pubmed:year |
2005
|
pubmed:articleTitle |
In vitro activity of beta-lactams and quinolones against AmpC beta-lactamase-producing Escherichia coli.
|
pubmed:affiliation |
Clinical Laboratory, Wakayama Rosai Hospital, 435 Koya, Wakayama, 640-8345, Japan. kyamasaki@gaia.eonet.ne.jp
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study
|